Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics.

Schreiner A, Lahaye M, Peuskens J, Naber D, Dilbaz N, Millet B, Franco MA, Rancans E, Turczynski J, Smeraldi E, Lara E, Neznanov NG.

Expert Opin Pharmacother. 2014 Apr;15(5):593-603. doi: 10.1517/14656566.2014.884071. Epub 2014 Feb 3.

PMID:
24491033
2.

Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.

Gattaz WF, Campos JA, Lacerda AL, Henna E, Ruschel SI, Bressan RA, de Oliveira IR, Rocha FL, Grabowski HM, Sacomani E Jr, Louzã MR, Quevedo J, Elkis H, Zorzetto Filho D, Périco Cde A, Lawson FL, Appolinário JC.

Curr Med Res Opin. 2014 Apr;30(4):695-709. doi: 10.1185/03007995.2013.869201. Epub 2013 Dec 16.

PMID:
24289141
3.

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M.

J Clin Psychiatry. 2008 May;69(5):817-29.

PMID:
18466043
4.

Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophrenia.

Helldin L, Peuskens J, Vauth R, Sacchetti E, Bij de Weg H, Herken H, Lahaye M, Schreiner A.

Ther Adv Psychopharmacol. 2015 Aug;5(4):194-207. doi: 10.1177/2045125315584870.

5.

A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.

Kotler M, Dilbaz N, Rosa F, Paterakis P, Milanova V, Smulevich AB, Lahaye M, Schreiner A.

J Psychiatr Pract. 2016 Jan;22(1):9-21. doi: 10.1097/PRA.0000000000000117.

6.

Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).

Schreiner A, Hargarter L, Hitschfield K, Lee JI, Lenskaya I, Sulaiman AH, Diels J; PILAR study group.

Curr Med Res Opin. 2014 Jul;30(7):1279-89. doi: 10.1185/03007995.2014.898630. Epub 2014 Mar 19.

PMID:
24597755
7.

Paliperidone extended release: a review of its use in the management of schizophrenia.

Chwieduk CM, Keating GM.

Drugs. 2010 Jul 9;70(10):1295-317. doi: 10.2165/11204840-000000000-00000. Review.

PMID:
20568835
8.

Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.

Jones MP, Nicholl D, Trakas K.

Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99.

PMID:
20497747
9.

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.

Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM.

BMC Psychiatry. 2011 Feb 7;11:21. doi: 10.1186/1471-244X-11-21.

10.

Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.

Schmauss M, Jukić V, Siracusano A, Bidzan L, Badescu GM, Maciulis V, Lahaye M, Hoeben D, Tessier C, Schreiner A.

Curr Med Res Opin. 2012 Aug;28(8):1395-404. doi: 10.1185/03007995.2012.708327. Epub 2012 Jul 19.

PMID:
22746355
11.
13.

Paliperidone extended-release for the treatment of schizophrenia.

Marino J, Caballero J.

Pharmacotherapy. 2008 Oct;28(10):1283-98. doi: 10.1592/phco.28.10.1283. Review.

PMID:
18823223
14.

Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.

Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, Kim JM, Shin IS, Yoon JS.

Int Clin Psychopharmacol. 2012 Sep;27(5):267-74. doi: 10.1097/YIC.0b013e328356acad.

PMID:
22809972
15.

The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.

Kim SW, Yoon JS, Kim YS, Ahn YM, Kim CE, Go HJ, Chee IS, Jung SW, Chung YC, Kim YD, Joe S, Lee J, Kwon YJ, Yoon BH, Jae YM.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):228-35. doi: 10.1016/j.pnpbp.2012.04.004. Epub 2012 Apr 10.

PMID:
22516251
16.

Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.

Fowler JA, Bettinger TL, Argo TR.

Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011. Review.

PMID:
18343262
17.

Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.

Kim EY, Chang SM, Shim JC, Joo EJ, Kim JJ, Kim YS, Ahn YM.

Curr Med Res Opin. 2013 Oct;29(10):1231-40. doi: 10.1185/03007995.2013.816277. Epub 2013 Jul 16.

PMID:
23777311
18.

Paliperidone extended release: in adolescents with schizophrenia.

Perry CM.

Paediatr Drugs. 2012 Dec 1;14(6):417-27. doi: 10.2165/11209900-000000000-00000. Review.

PMID:
23050744
19.

Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.

Amatniek J, Canuso CM, Deutsch SI, Henderson DC, Mao L, Mikesell C, Rodriguez S, Sheehan J, Alphs L.

Clin Schizophr Relat Psychoses. 2014 Apr;8(1):8-20. doi: 10.3371/CSRP.AMCA.021513.

PMID:
23428785
20.

A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.

Schreiner A, Bergmans P, Cherubin P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Hargarter L.

Clin Ther. 2014 Oct 1;36(10):1372-88.e1. doi: 10.1016/j.clinthera.2014.08.014. Epub 2014 Oct 23. Erratum in: Clin Ther. 2014 Nov 1;36(11):1705.

Supplemental Content

Support Center